Novartis won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said, days after Pfizer took a similar step following criticism from President Trump.
WSJ.com: Asia Home, Wall Street Journal: Home Asia
Wed, 07/18/2018 - 1:46pm
Novartis won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said, days after Pfizer took a similar step following criticism from President Trump.